

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 July 2009 (23.07.2009)

PCT

(10) International Publication Number
WO 2009/090024 A1

(51) International Patent Classification:

C07D 493/04 (2006.01) **A61P 35/00** (2006.01)
A61K 31/357 (2006.01)

(21) International Application Number:

PCT/EP2009/000112

(22) International Filing Date: 12 January 2009 (12.01.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

08000904.6 18 January 2008 (18.01.2008) EP

(71) Applicant (for all designated States except US): **INDENA S.p.A.** [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CICERI, Daniele** [IT/IT]; INDENA S.p.A., Viale Ortles, 12, I-20139 Milano (IT). **SARDONE, Nicola** [IT/IT]; INDENA S.p.A., Viale Ortles, 12, I-20139 Milano (IT). **GABETTA, Bruno** [IT/IT]; INDENA S.p.A., Viale Ortles, 12, I-20139 Milano (IT). **RICOTTI, Maurizio** [IT/IT]; INDENA S.p.A., Viale Ortles, 12, I-20139 Milano (IT).

(74) Agent: **MINOJA, Fabrizio**; BIANCHETTI BRACCO MINOJA S.r.l., Via Plinio, 63, I-20129 Milano (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: SOLID FORMS OF ORTATAXEL

(57) Abstract: The present invention relates to solid forms of 13-(N-Boc- β -isobutylserinyl)-14- β -hydroxybaccatin III 1,14-carbonate (Ortataxel). Amorphous Form A, crystalline Form B, mixtures thereof and processes for preparing them are disclosed. Amorphous Form A is prepared by fast precipitation of Ortataxel from a mixture of acetone and water. Form A transforms in Form B when suspended and stirred in a mixture of ethanol and water for 4-8 hours. If the suspension is stirred for less than 4 hours, mixtures of Form B and Form A are obtained. Form B or mixtures of Forms A and B can also be obtained dissolving Ortataxel in a protic organic solvent, followed by addition of water.


WO 2009/090024 A1

SOLID FORMS OF ORTATAXEL

Field of the invention

The present invention relates to solid forms of Ortataxel (13-(N-Boc- β -isobutylserinyl)-14- β -hydroxybaccatin III 1,14-carbonate) (1), mixtures thereof and methods for their preparation.


5



Background of the invention

Ortataxel (1) is an antitumor compound particularly active against breast, lung, ovary, colon, prostate, kidney and pancreas tumors, even in case of resistance to known antitumor agents such as adriamycin, vinblastine and some platinum derivatives.

10



Ortataxel can be prepared according to the methods described in U.S. 7,232,916, in U.S. 6,737,534 and in U.S. 6,906,101. These patents disclose in the examples a final purification step consisting of crystallization from a

15

mixture of acetone and hexane, which gives Ortataxel in the form of a solvate with an acetone content ranging from 4.5 to 6.5%.

The XRPD of the acetone solvate shows distinctive peaks at approximately 7.9, 9.8, 10.6, 10.9, 14.6, 16.9, 19.7, 21.3 deg 2-theta. The DSC curve shows an endothermic peak with onset at about 164°C due to melting and release of the crystallization solvent (confirmed by a weight loss of about 5.0% in TG/DTA) and a weak exothermic peak with maximum at about 212°C followed by an intense endothermic peak with maximum at about 247°C due to melting and incipient decomposition. The IR shows characteristic absorption frequencies at 3521, 3321, 2971, 2953, 1826, 1762, 1706, 1526, 1366, 1238, 1165, 1072, 723 cm⁻¹.

It is well known that volatile impurities in active pharmaceutical ingredients must comply with ICH (International Conference on Harmonisation) guidelines (Q3C); in this specific case an acetone content from 4.5 to 6.5% would not be allowed. Thus, it would be desirable to find a stable crystalline form of Ortataxel which does not contain residual solvents in amounts unacceptable from a regulatory point of view. Such crystalline form should also be chemically and thermodynamically stable, i.e. it should keep the same quality during storage, and should be obtainable through a reproducible method.

Disclosure of the invention

It has now been found that Ortataxel exists in two non-solvated physical Forms, herein after referred to as Forms A and B, which can also be obtained as mixtures.

Form A is an amorphous solid, since it shows an X-ray powder diffraction pattern with no discernable peaks. It can be easily prepared from Ortataxel, for example Ortataxel acetone solvate obtained according to the synthetic procedures described in the above-cited patents, by dissolution in a

suitable water-miscible solvent, followed by fast addition of water containing traces (usually 0.001-0.003% w/v) of an organic acid such as acetic or ascorbic acid, preferably citric. "Suitable water-miscible solvent" means a ketone or an aprotic dipolar solvent or a mixture thereof; preferred solvents are acetone, dimethylsulfoxide and mixtures thereof. The process is usually carried out at a temperature ranging from 20 to 30°C; and the preferred organic acid is citric acid. The organic acid avoids undesired formation of the 7-epimer and makes Form A physically and chemically stable for at least 36 months. According to a preferred embodiment, the preparation of Form A is carried out dissolving Ortataxel in acetone (8 mL/g_{ortataxel}) and precipitating it with a water (40 mL/g_{ortataxel}) containing 0.001-0.003% w/v citric acid, at room temperature.

Form B is a crystalline polymorph melting at 159°C; with respect to the pseudopolymorphic acetone solvate, Form B is characterized by a low solvent content, ease of isolation by filtration or centrifugation and chemical and physical stability for at least 36 months. Form B can be prepared dissolving Ortataxel, for example the acetone solvate or the above form A, in a protic organic solvent, such as methanol, ethanol or isopropanol, preferably ethanol, containing traces of an organic acid (0.01-0.03% w/v), such as acetic, ascorbic but preferably citric acid, followed by addition of water until precipitation and stirring the resulting mixture at a temperature ranging from 0 to 60°C, preferably at 40°C, for a time ranging from 4 to 8 hours. According to a preferred embodiment, the preparation of Form B is carried out dissolving Ortataxel in ethanol (8-12 mL/g_{ortataxel}) containing 0.01-0.03% w/v of citric acid, followed by addition of water (13-20 mL/g_{ortataxel}), so that the ethanol/water ratio ranges between 0.5-0.7, and stirring for 6 hours. If stirring is carried out for less than 4 hours, Ortataxel is obtained as a mixture of Form A and Form.

Ortaxel Forms A and B and mixtures thereof can advantageously be used for the preparation of pharmaceutical compositions for the treatment of cancer. In particular, mixtures of form A and B, which have different bioavailabilities, are useful for the preparation of controlled-release solid
5 Forms. Therefore, a further object of the present invention are pharmaceutical compositions containing Ortaxel crystalline Form A or B or mixtures thereof in admixture with pharmaceutically acceptable carriers and/or ingredients; for example those disclosed in "Remington's Pharmaceutical Sciences", Mack Publishing Co., N.Y., USA.

10 The invention is now illustrated in greater detail in the following experimental section.

EXPERIMENTAL SECTION

Description of the figures

X-ray powder diffraction (XRPD), differential scanning calorimetry
15 (DSC), thermogravimetric/differential thermal analyses (TG/DTA), infrared (IR), and optical microscopy were used to characterize the new solid Forms which are compared with the analytical data of the acetone solvate.

Figures 1-4: XRPD, DSC, TG/DTA and IR spectra of Form A;

Figures 5-8: XRPD, DSC, TG/DTA and IR spectra of Form B;

20 Figures 9-12: XRPD, DSC, TG/DTA and IR spectra of a mixture of Form A and Form B, containing about 75% of Form B;

Figure 13: DSC profile of different proportions of Form A and Form B.

Form A

The x-ray powder diffraction pattern of Form A (Fig.1) is typical for an
25 amorphous product with complete absence of diffraction peaks.

The DSC curve of Form A (Fig. 2) shows a weak and broad endothermic signal with maximum at about 80°C, a baseline deflection due to T_g between 133°C and 143°C, an exothermic peak with maximum at about

214°C due to recrystallisation of the melted product and the consequent melting peak with maximum at about 246°C followed by decomposition.

The IR spectrum of Form A (figure 3) shows the characteristic absorption frequencies at 3442, 2960, 1821, 1732, 1714, 1368, 1236, 1162,
5 1085, 1068, 984, 907, 776, 763, 711 cm⁻¹.

The TG/DT analysis of Form A (fig 4) confirms the DSC analysis showing a DT profile characterized by a baseline deflection due to T_g between 130°C and 143°C, an exothermic peak with maximum at about 211°C due to recrystallisation of the melted product and the consequent
10 melting peak with maximum at about 249°C followed by decomposition. The TG profile shows a weight loss of about 1.0% from 30 to 150°C due to release of residual moisture and a weight loss of about 1.6% which takes place upon recrystallisation followed by a massive weight loss due to a degradative reaction.

15 The optical microscopy shows that solid Form A is constituted by a glassy irregular particulate with a large variety of dimensions and absence of well-shaped crystal Forms.

Form B

The x-ray powder diffraction pattern of Form B (Fig. 5) shows a
20 crystalline structure with useful distinctive peaks at approximately 3.5, 6.8, 9.9, 10.1, 10.7, 12.1, 13.1, 14.8, 18.2, 19.7, 21.3, 29.3 deg 2-theta.

The DSC curve of Form B (fig 6) shows a weak and broad endothermic signal with maximum below 100°C, a first melting peak with maximum at about 166°C and ΔH_{fus} of about -20 J/g, an exothermic peak with maximum
25 at about 196°C due to recrystallisation of the melted product and a second melting peak with maximum at about 252°C followed by decomposition.

The IR spectrum of Form B (fig.) 7 shows the characteristic absorption frequencies at 3444, 2961, 1816, 1735, 1720, 1689, 1368, 1237, 1163, 1085,

1068, 1047, 989, 949, 907, 776, 764, 710 cm⁻¹.

The TG/DT analysis of Form B (fig 8) confirms the DSC analysis showing a weak and broad endothermic signal with maximum below 100°C due to release of residual moisture, a first melting peak with maximum at about 164°C, an exothermic peak with maximum at about 200°C due to recrystallisation of the melted product and a second melting peak with maximum at about 253°C followed by decomposition. In the TG profile, a weight loss of about 1.4% from 30 to 150°C due to release of residual moisture is followed by a massive weight loss which takes place above 240°C due to a degradative reaction.

The optical microscopy shows that solid Form B is constituted by acicular (needle-like) crystals.

Mixture of Form A and Form B

The x-ray powder diffraction pattern of the mixture of Form A and Form B (Fig. 9) shows a crystalline structure with distinctive peaks at approximately 3.4, 6.8, 9.9, 10.6, 12.1, 13.1, 14.8, 18.1, 19.7, 21.2 deg 2-theta due to the fraction of Form B in the mixture.

The DSC curve (fig 10) shows a weak and broad endothermic signal with maximum below 100°C, a first melting peak with maximum at about 163°C and ΔH_{fus} of about -15 J/g, an exothermic peak with maximum at about 202°C due to recrystallisation of the melted product and a second melting peak with maximum at about 251°C followed by decomposition.

The IR spectrum (figure 11) shows characteristic absorption frequencies at 3448, 2960, 1816, 1735, 1719, 1688, 1368, 1237, 1164, 1085, 1068, 1048, 989, 949, 906, 776, 764, 710 cm⁻¹.

The TG/DT analysis (fig 12) confirms the DSC analysis showing a weak and broad endothermic signal with maximum below 100°C due to release of residual moisture, a first melting peak with maximum at about

162°C, an exothermic peak with maximum at about 202°C due to recrystallisation of the melted product and a second melting peak with maximum at about 250°C, followed by decomposition. In the TG profile, a weight loss of about 2.7% from 30 to 150°C due to release of residual
5 moisture is followed by a massive weight loss which takes place at 240°C due to a degradative reaction.

Optical microscopy shows that the Mixture of Form A and Form B is constituted by prismatic crystals.

These data clearly indicate that polymorphic Forms A and B of
10 Ortataxel are easily distinguishable from the pseudopolymorphic acetone solvate by means of XRPD, DSC, IR and analyses for the solvent content (such as thermogravimetry or gas-chromatography).

MATERIALS AND METHODS

X-Ray Powder Diffraction Pattern (xrpd)

15 X-ray powder diffraction patterns were collected on a Philips PW1800 diffractometer. The x-ray generator was operated at 45 kV and 40 mA, using the Cu K α line as radiation source. The sample was packed on a suitable slit and the irradiated length was 10 mm. The data were collected between 2 and 65 deg 2-theta with a step size of 0.02 deg 2-theta.

Differential Scanning Calorimetry (DSC)

Measurements of differential scanning calorimetry were performed using a Mettler TC15 System equipped with a DSC20 measuring cell, using closed aluminum crucibles (40 μ l volume) with a pinhole. Heat flow was recorded from 30 to 300°C with a linear heating rate of 10°C/min under a 50
25 ml/min nitrogen flow. About 5 mg of powder was used for each measurement.

Thermogravimetry and differential thermal analysis (TG/DTA)

The analyses were performed using a Seiko TG/DTA6200 simultaneous system using open aluminum pans (40 μ l volume). The TG/DT

signals were recorded from 30 to 300°C with linear heating rate (10°C/min) under a 200 ml/min nitrogen flow. About 10 mg of powder was used for each measurement.

Fourier transform infrared spectroscopy (FTIR)

- 5 The infrared spectra were recorded with ATR technique using a Fourier-transform spectrometer Perkin Elmer Spectrum One. The spectra were the result of the acquisition and transformation of 16 co-added scans in the 4000-550 cm^{-1} spectral region at a resolution of 4 cm^{-1} .

Optical microscopy

- 10 The analyses were performed using a transmitted-light microscope Zeiss Axioskop. For each analysis a little amount of sample was dispersed in silicone oil, mounted on a specimen slide and covered with a micro cover glass. The observations were carried out under appropriate conditions of illumination, contrast and magnification.

15 **EXAMPLE 1 - Preparation of Form A**

- Ortataxel (13 g) was dissolved in acetone (112.5 mL). Purified water (555 mL) containing citric acid (12 mg) was rapidly added under stirring, causing the precipitation of an amorphous solid which was filtered and washed with water (65 mL) containing citric acid (18 mg). The sample was
20 dried at 40°C for 48 hours affording 12 g of a white solid having the characteristic XRPD, DSC, IR and TG/DTA reported in figures 1-4 respectively.

EXAMPLE 2 - Preparation of Form B

- Ortataxel (14 g) was dissolved in 95% ethanol (168 mL) containing
25 citric acid (28 mg) at 50°C. Cold demineralised water (280 mL) was added to the resulting solution over 15 minutes. The suspension was stirred at 40°C for 6 hours. The mixture was cooled down to 20°C and the white solid was filtered off. The solid was washed with a solution of ethanol (168 mL) and

water (280 mL). The solid was dried under vacuum at 50°C for 40 hours affording 13.4 g of a white solid having the characteristic XRPD, DSC, IR and TG/DTA reported in figures 5-8 respectively.

EXAMPLE 3 - Preparation of a mixture of about 25% Form A and 75%

5 Form B

Ortataxel (14 g) was dissolved in 95% ethanol (168 mL) containing citric acid (28 mg) at 50°C. Cold demineralised water (280 mL) was added to the resulting solution over 15 minutes. The mixture was promptly cooled down to 20°C and the white solid was filtered off. The solid was washed with
10 a solution of ethanol (168 mL) and water (280 mL) containing citric acid (25 mg). The solid was dried under vacuum at 50°C for 40 hours affording 13.4 g of white material having the characteristic XRPD, DSC, IR and TG/DTA reported in figures 9-12 respectively.


**EXAMPLE 4 - Preparation of mixtures of Form A and Form B in
15 various proportions**

Form A (1 g) was suspended in a mixture of 95% ethanol (12 mL) and water (20 mL) containing citric acid (2 mg) at 40°C. Samples were taken at different times (t=0, t =5 min, t = 30 min, t = 6 h) in order to demonstrate that different proportions of Form A and Form B can be obtained. Figure 13 shows
20 the DSC analysis of the samples compared to the curve of pure Form B.

CLAIMS


1. Ortataxel [13-(N-Boc- β -isobutylserinyl)-14- β -hydroxybaccatin III
1,14-carbonate] (1)

5



amorphous Form A.

2. Process for preparing amorphous Form A of claim 1, which comprises dissolving Ortataxel in a ketone or in an aprotic dipolar organic solvent,
10 followed by addition of water containing 0.001-0.003% w/v of an organic acid.
3. The process according to claim 2 wherein the solvent is acetone or dimethylsulfoxide.
4. The process according to claim 2 or 3 wherein the organic acid is citric or ascorbic acid.
- 15 5. The process according to claim 3 wherein the organic acid is citric acid.
6. Ortataxel [13-(N-Boc- β -isobutylserinyl)-14- β -hydroxybaccatin III
1,14-carbonate] (1)



crystalline Form B of having the XRPD characterized by the following peaks 3.5, 6.8, 9.9, 10.1, 10.7, 12.1, 13.1, 14.8, 18.2, 19.7, 21.3, 29.3 deg 2-theta.

7. A process for the preparation of Ortataxel Form B of claim 6, which comprises dissolving Ortataxel in ethanol containing traces of an organic
5 acidic, followed by addition of water and stirring at a temperature ranging from 0 to 60°C for a time ranging from 4 to 8 hours.
8. The process of claim 7 wherein the Ortataxel dissolved in ethanol is Ortataxel acetone solvate or Ortataxel form A as defined in claim 1.
9. The process according to claim 7 or 8 wherein the temperature is
10 40°C.
10. The process according to claim 9 wherein stirring is carried out for 6 hours.
11. The process according to any one of claims 8 to 10 wherein the organic acid is citric acid.
- 15 12. Mixtures of Ortataxel Form A as defined in claim 1 and Form B as defined in claim 6.
13. A mixture as defined in claim 12 wherein the amount of Form B is about 75% by weight.
14. A process for the preparation of the mixtures of Form A and Form B as
20 defined in claim 12 or 13, which comprises suspending Ortataxel in a mixture of ethanol and water containing an organic acid and stirring for less than 4 hours and at a temperature ranging from 0 to 60°C.
15. The process according to claim 14 wherein the Ortataxel suspended in the mixture of ethanol and water is Ortataxel acetone solvate or Ortataxel
25 Form A.
16. The process according to claim 15 wherein ethanol and water are in a 0.5-0.7 ratio.
17. The process according to claim 16 wherein the temperature is 40°C.

18. The process according to any one of claims 15 - 17 wherein the organic acid is citric acid or ascorbic acid.

19. The process according to claim 18 wherein the organic acid is citric acid.

5 20. Pharmaceutical compositions containing Ortataxel amorphous form A as defined in claim 1 or Ortataxel crystalline form B as defined in claim 5 or mixtures thereof as defined in claim 12 or 13 in admixture with suitable excipients and/or carriers.

21. Use of Ortataxel amorphous form A as defined in claim 1 or of
10 Ortataxel crystalline form B as defined in claim 6 or of mixtures thereof as defined in claim 12 or 13 for the preparation of pharmaceutical compositions for the treatment of cancer.

Fig. 1 - XRPD diffractogram of Form A




Fig. 2 - DSC profile of Form A




Fig. 3 - FTIR spectrum of Form A




Fig. 4 - TG/DT profile of Form A




Fig.5 - XRPD diffractogram of Form B




Fig. 6 - DSC profile of Form B




Fig. 7 - FTIR spectrum of Form B




Fig. 8 - TG/DT profile of Form B




Fig. 9 - XRPD diffractogram of Mixture of Form A and Form B




Fig. 10 - DSC profile of Mixture of Form A and Form B




Fig. 11 - FTIR spectrum of Mixture of Form A and Form B




Fig.12 - TG/DT profile of Mixture of Form A and Form B





Fig 13. - DSC profile of different proportions of Form A and Form B



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2009/000112

A. CLASSIFICATION OF SUBJECT MATTER INV. C07D493/04 A61K31/357 A61P35/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2007/212394 A1 (REYES PRISCILLA [US] ET AL) 13 September 2007 (2007-09-13) page 23, paragraph 172 -----	1-21
A	US 7 232 916 B1 (GABETTA BRUNO [IT] ET AL) 19 June 2007 (2007-06-19) cited in the application column 10; example 6; compound I -----	1-21
A	WO 02/44161 A (INDENA SPA [IT]; PONTIROLI ALESSANDRO [IT]; BOMBARDELLI EZIO [IT]) 6 June 2002 (2002-06-06) cited in the application page 16, line 3 -----	1-21
-/--		
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*&* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">10 March 2009</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">28/05/2009</div>
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Gutke, Hans-Jürgen</div>

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2009/000112

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/02407 A (INDENA SPA [IT]; BOMBARDELLI EZIO [IT]; GABETTA BRUNO [IT]; PONTIROLI) 11 January 2001 (2001-01-11) cited in the application page 27, line 22	1-21
A	----- HENNENFENT K L ET AL: "NOVEL FORMULATIONS OF TAXANES: A REVIEW. OLD WINE IN A NEW BOTTLE?" ANNALS OF ONCOLOGY, KLUWER, DORDRECHT, NL, vol. 17, no. 5, 2006, pages 735-749, XP008065745 ISSN: 0923-7534 page 745	1-21
A	----- WO 2007/078050 A (SAMYANG GENEX CORP [KR]; PYO SANG-HYUN [KR]; CHO JIN-SUK [KR]; KIM MOO) 12 July 2007 (2007-07-12) pages 15-16; example 1	1-21
A	----- NICOLETTI MARIA INES ET AL: "IDN5109, a taxane with oral bioavailability and potent antitumor activity" CANCER RESEARCH, vol. 60, no. 4, 15 February 2000 (2000-02-15), pages 842-846, XP002478136 ISSN: 0008-5472 page 843	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2009/000112

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2007212394	A1	13-09-2007	NONE
US 7232916	B1	19-06-2007	NONE
WO 0244161	A	06-06-2002	AT 275149 T 15-09-2004 AU 2956302 A 11-06-2002 AU 2002229563 B2 30-03-2006 CA 2430070 A1 06-06-2002 CN 1478091 A 25-02-2004 CZ 20031474 A3 13-08-2003 DE 60105314 D1 07-10-2004 DE 60105314 T2 29-09-2005 EP 1347984 A2 01-10-2003 ES 2227316 T3 01-04-2005 HK 1059778 A1 04-08-2006 HU 0302765 A2 28-11-2003 IT MI20002553 A1 28-05-2002 JP 2004519434 T 02-07-2004 NO 20032401 A 27-05-2003 PL 362392 A1 02-11-2004 PT 1347984 T 30-11-2004 RU 2275365 C2 27-04-2006 SK 6422003 A3 04-11-2003 TR 200402546 T4 21-12-2004 US 2004030164 A1 12-02-2004
WO 0102407	A	11-01-2001	AT 277932 T 15-10-2004 AT 350372 T 15-01-2007 AU 771737 B2 01-04-2004 AU 5823500 A 22-01-2001 CA 2373530 A1 11-01-2001 CN 1359384 A 17-07-2002 CN 1539831 A 27-10-2004 CN 1769275 A 10-05-2006 CZ 20020022 A3 15-05-2002 DE 60014374 D1 04-11-2004 DE 60014374 T2 16-02-2006 DE 60032827 T2 08-11-2007 DK 1529777 T3 14-05-2007 EP 1192162 A2 03-04-2002 ES 2228560 T3 16-04-2005 ES 2278254 T3 01-08-2007 HK 1047096 A1 22-04-2005 HK 1068879 A1 25-08-2006 HU 0202016 A2 28-10-2002 IT MI991483 A1 08-01-2001 JP 2003503502 T 28-01-2003 NO 20020017 A 27-02-2002 PL 352278 A1 11-08-2003 PT 1192162 T 31-12-2004 SK 12002 A3 04-04-2002 US 6906101 B1 14-06-2005
WO 2007078050	A	12-07-2007	EP 1973894 A2 01-10-2008 KR 20070072786 A 05-07-2007 US 2009018353 A1 15-01-2009